Immunohistochemistry is the most frequently used test to evaluate the HER-2 status in breast cancer and screening [56], though there are issues with the accuracy and consistency of immunohistochemistry results acquired from different laboratories. This evidence concerns the gene ERBB2 and breast cancer.